DexCom added Dr. Euan Ashley to its board of directors, effective October 24, 2025, following the departure of Dr. Eric Topol. The appointment expands DexCom’s board to ten directors, with a planned increase to eleven on January 1, 2026.
Ashley, chair of Stanford University’s Department of Medicine, brings a deep clinical and research background, having led Stanford’s largest medical department and overseen more than 800 faculty. He co‑founded seven biotechnology companies, including Personalis, Deepcell, Svexa, Saturnus Bio, and Swift Bio, and was elected to the National Academy of Medicine in October 2025.
In addition to his role at Stanford, Ashley serves as a non‑executive director on AstraZeneca’s board and chairs its Science Committee. At DexCom, he will sit on the Nominating and Governance Committee and the Technology Committee, where he will advise on AI, data analytics, and metabolic health strategy.
DexCom’s board expansion reflects the company’s focus on broadening its metabolic health portfolio and integrating advanced data science into its glucose‑biosensing platform.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.